Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 32,914 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo-Control Clear all
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease

NCT02633020
View directory record Official record
Conditions
Type II Refractory Celiac Disease (RCD-II), In-situ Small Bowel T-cell Lymphoma
Interventions
AMG 714, Placebo
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
San Diego, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2019 · Synced Oct 22, 2026, 5:20 AM EDT
Completed Phase 2 Interventional

Multiple Ascending Dose Study of Miravirsen in Treatment-Naïve Chronic Hepatitis C Subjects

NCT01200420
View directory record Official record
Conditions
Hepatitis C
Interventions
miravirsen, saline
Drug
Lead sponsor
Santaris Pharma A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2012 · Synced Oct 22, 2026, 5:20 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis

NCT02357420
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus Complications, Gastroparesis
Interventions
Relamorelin, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
70
States / cities
Dothan, Alabama • Huntsville, Alabama • Tucson, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 22, 2026, 5:20 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study to Evaluate the Impact of MTP-131 (Bendavia™) on Skeletal Muscle Function in Elderly

NCT02245620
View directory record Official record
Conditions
Skeletal Muscle Mitochondrial Dysfunction in the Elderly
Interventions
Elamipretide, Placebo
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
60 Years to 85 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 23, 2020 · Synced Oct 22, 2026, 5:20 AM EDT
Completed Not applicable Interventional

Effect of Calcium Polycarbophil on Type II Diabetes Mellitus Control: a Randomized Double-blind Study

NCT01252524
View directory record Official record
Conditions
Diabetes Mellitus Type II
Interventions
Placebo, Calcium polycarbophil
Drug
Lead sponsor
East Carolina University
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 22, 2026, 5:20 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Apo805K1 in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT01483924
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Apo805K1
Drug
Lead sponsor
ApoPharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Los Angeles, California • Dallas, Texas • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2015 · Synced Oct 22, 2026, 5:20 AM EDT
Recruiting Phase 4 Interventional

A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.

NCT07053423
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 85 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
11
States / cities
Birmingham, Alabama • Miami, Florida • Cordele, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 22, 2026, 5:20 AM EDT
Active, not recruiting Phase 3 Interventional

Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

NCT03997123
View directory record Official record
Conditions
Triple Negative Breast Neoplasms
Interventions
Capivasertib, Paclitaxel, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
923 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
22
States / cities
Whittier, California • Fort Myers, Florida • Miami, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 22, 2026, 5:20 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.

NCT06247735
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
K-808 (Dose A), K-808 (Dose B), Placebo
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
21
States / cities
Tucson, Arizona • Coronado, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 22, 2026, 5:20 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Study to Assess the Efficacy of Once-daily IMM-124E (Travelan®) in a Controlled Human Infection Model.

NCT05933525
View directory record Official record
Conditions
Diarrhea, Travelers Diarrhea, Infectious Diarrhea
Interventions
Travelan, Placebo
Biological · Other
Lead sponsor
Immuron Ltd.
Industry
Eligibility
18 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 22, 2026, 5:20 AM EDT
Completed Phase 4 Interventional Results available

Amitiza in Constipation Associated With PD (Parkinson's Disease)

NCT00908076
View directory record Official record
Conditions
Parkinson's Disease
Interventions
LUBIPROSTONE
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 85 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Tampa, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 29, 2022 · Synced Oct 22, 2026, 5:20 AM EDT
Completed Phase 2 Interventional Results available

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer

NCT01395017
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
dasatinib, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2016 · Synced Oct 22, 2026, 5:20 AM EDT
Not yet recruiting Phase 3 Interventional

A Study of Combogesic® 325 in Adolescent Patients With Moderate to Severe Postoperative Pain Associated With Orthopedic Surgery

NCT07225140
View directory record Official record
Conditions
Post Operative Pain, Acute
Interventions
Combogesic® tablets, Acetaminophen 500mg, Placebo
Drug
Lead sponsor
AFT Pharmaceuticals, Ltd.
Industry
Eligibility
12 Years to 17 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 22, 2026, 5:20 AM EDT
Completed Phase 2 Interventional

HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes

NCT05623189
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH), Type 2 Diabetes
Interventions
HTD1801, Placebo
Drug
Lead sponsor
HighTide Therapeutics (Hong Kong) Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
43
States / cities
Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 22, 2026, 5:20 AM EDT
Completed Phase 3 Interventional Results available

A Trial Evaluating the Efficacy and Safety of HLD200 in Children With ADHD

NCT02255513
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
HLD200, Placebo
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
6 Years to 12 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
4
States / cities
Newport Beach, California • Marshfield, Massachusetts • Las Vegas, Nevada + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 22, 2026, 5:20 AM EDT
Terminated Phase 2 Interventional

Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease

NCT02074410
View directory record Official record
Conditions
Huntington's Disease
Interventions
OMS643762, Placebo
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
9
States / cities
San Diego, California • Englewood, Colorado • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Oct 22, 2026, 5:20 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Cognizin Citicoline Dosing in a Healthy Adolescent Male Population

NCT01582113
View directory record Official record
Conditions
Neurocognitive Improvement
Interventions
Citicoline, Microcrystalline Cellulose
Drug · Other
Lead sponsor
Deborah Yurgelun-Todd
Other
Eligibility
13 Years to 18 Years · Male only
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Oct 22, 2026, 5:20 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety Eval of Guanfacine Hydrochloride in Combination With Psychostimulants in Adults (18-65).

NCT02141113
View directory record Official record
Conditions
Adult Attention-Deficit Hyperactivity Disorder
Interventions
Guanfacine Hydrochloride, Placebo
Drug · Other
Lead sponsor
Rochester Center for Behavioral Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Rochester Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 22, 2026, 5:20 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Dose Response of Epinephrine

NCT02692313
View directory record Official record
Conditions
Diabetes Complications
Interventions
Epinephrine, Saline infusion
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 22, 2026, 5:20 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer

NCT01829113
View directory record Official record
Conditions
Non Squamous Non Small Cell Lung Cancer
Interventions
OGX-427, Placebo
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
16
States / cities
Denver, Colorado • Fort Myers, Florida • Orlando, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2018 · Synced Oct 22, 2026, 5:20 AM EDT
Completed Phase 2 Interventional

A Study of a Topical Patch (AB001) in Patients With Chronic Low Back Pain

NCT02436824
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
AB001 patch, Placebo patch
Drug · Other
Lead sponsor
Frontier Biotechnologies Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
9
States / cities
Miami, Florida • Naples, Florida • Marietta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Oct 22, 2026, 5:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating the Potentials of Biodynamic Lighting for Home Office Workers

NCT05481424
View directory record Official record
Conditions
Cognitive Performance, Sleep, Alertness
Interventions
Biodynamic, Active Placebo
Other
Lead sponsor
Arizona State University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 22, 2026, 5:20 AM EDT
Terminated Phase 2 Interventional Results available

A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001)

NCT04583423
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
MK-3655, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
48
States / cities
Tucson, Arizona • North Little Rock, Arkansas • Canoga Park, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 22, 2026, 5:20 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

A Clinical Study to Evaluate the Efficacy of Activated Silk™ 27P-α in Subjects, Aged 35-65 Years of Age, to Improve the Signs of Aging

NCT06804759
View directory record Official record
Conditions
Skin Aging
Interventions
Investigational Facial Serum #1, Investigational Facial Serum #2, Investigational Facial Serum #3
Other
Lead sponsor
Victoria Collotta
Industry
Eligibility
35 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 22, 2026, 5:20 AM EDT